BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15646648)

  • 21. Stellae-123 gene expression signature improved risk stratification in taiwanese acute myeloid leukemia patients.
    Wang YH; Orgueira AM; Lin CC; Yao CY; Lo MY; Tsai CH; de la Fuente Burguera A; Hou HA; Chou WC; Tien HF
    Sci Rep; 2024 May; 14(1):11064. PubMed ID: 38744924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The implication of lncRNA expression pattern and potential function of lncRNA RP4-576H24.2 in acute myeloid leukemia.
    Zheng J; Song Y; Li Z; Tang A; Fei Y; He W
    Cancer Med; 2019 Dec; 8(17):7143-7160. PubMed ID: 31568697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. lncRNA co-expression network model for the prognostic analysis of acute myeloid leukemia.
    Pan JQ; Zhang YQ; Wang JH; Xu P; Wang W
    Int J Mol Med; 2017 Mar; 39(3):663-671. PubMed ID: 28204819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients.
    Rapin N; Bagger FO; Jendholm J; Mora-Jensen H; Krogh A; Kohlmann A; Thiede C; Borregaard N; Bullinger L; Winther O; Theilgaard-Mönch K; Porse BT
    Blood; 2014 Feb; 123(6):894-904. PubMed ID: 24363398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML?
    Willman CL
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):21-8. PubMed ID: 18342809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression profiling of cancer-related galectins in acute myeloid leukemia.
    El Leithy AA; Helwa R; Assem MM; Hassan NH
    Tumour Biol; 2015 Sep; 36(10):7929-39. PubMed ID: 25953264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia.
    Guo C; Gao YY; Ju QQ; Zhang CX; Gong M; Li ZL
    BMC Cancer; 2020 Sep; 20(1):841. PubMed ID: 32883226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis.
    Weber S; Haferlach T; Haferlach C; Kern W
    Blood Cancer J; 2016 Dec; 6(12):e507. PubMed ID: 27935581
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.
    Aref S; Azmy E; El Ghannam D; Haroun M; Ibrahim L; Sabry M
    Cancer Biomark; 2020; 29(1):9-16. PubMed ID: 32417762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct prognostic values of Annexin family members expression in acute myeloid leukemia.
    Niu Y; Yang X; Chen Y; Jin X; Xie Y; Tang Y; Li L; Liu S; Guo Y; Li X; Duan L; Wang H
    Clin Transl Oncol; 2019 Sep; 21(9):1186-1196. PubMed ID: 30694461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Pratcorona M; Abbas S; Kuipers JE; van Galen JF; Beverloo HB; Sonneveld E; Kaspers GJ; Trka J; Baruchel A; Zimmermann M; Creutzig U; Reinhardt D; Pieters R; Valk PJ; Zwaan CM
    Blood; 2011 Sep; 118(13):3645-56. PubMed ID: 21813447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.
    Rockova V; Abbas S; Wouters BJ; Erpelinck CA; Beverloo HB; Delwel R; van Putten WL; Löwenberg B; Valk PJ
    Blood; 2011 Jul; 118(4):1069-76. PubMed ID: 21596848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia.
    Kamijo R; Itonaga H; Kihara R; Nagata Y; Hata T; Asou N; Ohtake S; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Naoe T; Kiyoi H; Miyazaki Y
    Leuk Res; 2018 Feb; 65():34-41. PubMed ID: 29306105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low SMC1A protein expression predicts poor survival in acute myeloid leukemia.
    Hömme C; Krug U; Tidow N; Schulte B; Kühler G; Serve H; Bürger H; Berdel WE; Dugas M; Heinecke A; Büchner T; Koschmieder S; Müller-Tidow C
    Oncol Rep; 2010 Jul; 24(1):47-56. PubMed ID: 20514443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signature.
    Volpe G; Walton DS; Grainger DE; Ward C; Cauchy P; Blakemore D; Coleman DJL; Cockerill PN; Garcia P; Frampton J
    Sci Rep; 2017 Sep; 7(1):11148. PubMed ID: 28894287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.
    He PF; Xu ZJ; Zhou JD; Li XX; Zhang W; Wu DH; Zhang ZH; Lian XY; Yao XY; Deng ZQ; Lin J; Qian J
    J Cell Physiol; 2018 Sep; 233(9):6604-6614. PubMed ID: 29150948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
    Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
    Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.